Ribociclib maintenance therapy (initiated 72 hrs after initial treatment with cisplatin), potently synergized with cisplatin in the COV504, PEO1, and Hey1 ovarian cancer cell lines; in fact, control cells recovered effectively after cisplatin therapy, while cells treated with 1 uM or 3 uM Ribociclib as maintenance after cisplatin therapy remained unable to proliferate throughout the two-week observation period (Figure 4D; Supplementary Figure 3A). The gene discussed is HEY1; the disease is ovarian cancer.